HOME
ABOUT US
OUR COMPANY
OUR TEAM
BOARD OF DIRECTORS
INVESTORS
CAREERS
T-GUARD®
CHARACTERISTICS
DEVELOPMENT PLAN
GRAFT-VERSUS-HOST
ADDITIONAL INDICATIONS
EXPANDED ACCESS
A PATIENT’S STORY
NEWS & EVENTS
NEWS
EVENTS
IN THE MEDIA
PARTNERING
PARTNERING FOR PROGRESS
CONTACT
NEWS
3 januari 2017
EUR 1 million innovation credit to support T-Guard® development
2 november 2016
Xenikos appoints Eric van Hooren as Chief Development Officer
25 oktober 2016
Xenikos to participate in BIO-Europe® International Partnering Conference
14 oktober 2016
New financing triggered by promising preliminary data from ongoing Phase 1/2 study
20 september 2016
Participation in 3PBio Forum technology transfer panel at BIOSPAIN 2016
15 september 2016
Last patient treated in Phase 1/2 trial with T-Guard® in acute GVHD disease
24 mei 2016
Introduction T-Guard® to potential pharmaceutical partners at BIO 2016
4 januari 2016
Graft versus Host Disease (GVHD) Study Delivers Promising Interim Results
1 oktober 2015
Clinical Study of T-Guard® in the Treatment of GVHD extends to Germany
Load more
